Whether you call it 'bionic' or 'artificial,' it's destined to revolutionize diabetes care but still fall short of some patients' expectations. Howard Zisser talks with Anne Peters at ADA 2014.
Whether you call it 'bionic' or 'artificial,' it's destined to revolutionize diabetes care but still fall short of some patients' expectations. Howard Zisser talks with Anne Peters at ADA 2014.